Cataract (Adult)

1. Clinical Overview

A cataract is defined as any opacity of the crystalline lens that interferes with the passage of light to the retina, resulting in reduced visual acuity. Cataracts represent the leading cause of reversible blindness worldwide, accounting for approximately 51% of global blindness (20 million people). [1,2]

The condition is predominantly age-related, with prevalence increasing exponentially after age 40. In high-income countries, cataract surgery is the most commonly performed elective surgical procedure, with over 400,000 operations performed annually in the United Kingdom alone. [3]

Key Clinical Concepts

Reversible Blindness: Unlike many causes of vision loss (e.g., glaucoma, macular degeneration), cataracts are entirely reversible through surgical intervention, making early detection and appropriate referral critically important.

Progressive Nature: Cataracts progress at variable rates depending on type and underlying etiology. Nuclear sclerotic cataracts typically progress slowly over years, while posterior subcapsular cataracts (especially steroid-induced) may progress rapidly over months.

Quality of Life Impact: Beyond visual acuity, cataracts significantly impair quality of life through glare disability, reduced contrast sensitivity, and color desaturation—symptoms not fully captured by standard Snellen acuity testing.

---

2. Epidemiology

Global Burden

Exam Detail: Cataracts remain the leading cause of blindness globally despite being surgically curable. The WHO Global Burden of Disease Study estimates that cataracts account for 51% of world blindness, affecting approximately 20 million individuals. [1] The disparity in cataract surgical coverage between high-income and low-income countries contributes significantly to this burden.

*CSR = number of cataract surgeries per million population per year [2]

Age-Specific Prevalence

The prevalence of lens opacities increases exponentially with age:

Data from the Beaver Dam Eye Study and Blue Mountains Eye Study [4,5]

Sex Distribution

Cataracts show a slight female predominance (female:male ratio approximately 1.3:1), likely due to:

• Longer life expectancy in women
• Hormonal factors (decreased estrogen post-menopause may accelerate lens aging)
• Potentially higher prevalence of risk factors (e.g., corticosteroid use for autoimmune conditions) [6]

Ethnic Variations

Significant ethnic variations exist in cataract prevalence and type:

• Nuclear sclerotic cataracts: More common in Asian populations
• Cortical cataracts: Higher prevalence in African and Hispanic populations
• Posterior subcapsular cataracts: Similar rates across ethnic groups [7]

---

3. Risk Factors

Non-Modifiable Risk Factors

Modifiable Risk Factors

Exam Detail: Smoking: The strongest modifiable risk factor, conferring a 2-3× increased risk in current smokers. The risk is dose-dependent and partially reversible with cessation. Mechanisms include:

• Direct oxidative damage to lens proteins
• Reduced plasma antioxidant levels (vitamin C, vitamin E)
• Cadmium accumulation in lens tissue [8,9]

Ultraviolet (UV) Radiation: Cumulative UV-B exposure (280-315 nm wavelength) increases cortical cataract risk by 1.5-2.0×. UV radiation generates reactive oxygen species (ROS) that damage lens proteins and membrane lipids. [10]

Alcohol Consumption: Heavy alcohol intake (> 2 drinks/day) associated with 1.5-2.0× increased risk, particularly for nuclear cataracts. Mechanism involves acetaldehyde-mediated oxidative stress. [11]

Medical Conditions Associated with Cataracts

Exam Detail: Diabetes Mellitus: Diabetic patients develop cataracts 10-20 years earlier than non-diabetics and have 2-5× increased risk. [12] Three mechanisms operate:

1. Sorbitol Pathway: Hyperglycemia → aldose reductase converts glucose to sorbitol in lens → osmotic stress and fiber swelling → "snowflake cataract" (classic acute presentation in young diabetics with very poor control)

2. Advanced Glycation End-Products (AGEs): Non-enzymatic glycation of lens crystallins → protein cross-linking and aggregation → nuclear sclerosis

3. Oxidative Stress: Chronic hyperglycemia → increased ROS production → lipid peroxidation and protein oxidation

Drug-Induced Cataracts

Clinical Pearl: Corticosteroid-Induced Cataracts: The most common iatrogenic cause of cataracts. Risk is dose-dependent and cumulative:

• Risk threshold: > 10 mg prednisolone equivalent daily for > 1 year
• Latency: 6 months to several years
• Type: Posterior subcapsular (PSC) cataracts
• Routes: ALL routes carry risk—systemic, inhaled, topical ophthalmic, intranasal, dermal
• Mechanism: Corticosteroids bind to glucocorticoid receptors in lens epithelial cells → altered gene expression → abnormal lens fiber differentiation and migration → posterior subcapsular opacities [13,14]

Inhaled Corticosteroids: Often overlooked source. High-dose inhaled corticosteroids (e.g., fluticasone > 1000 mcg/day, budesonide > 800 mcg/day) for > 3 years carry significant risk, particularly in elderly patients.

Ocular Conditions

Trauma

---

4. Pathophysiology

Normal Lens Structure and Function

The crystalline lens is a biconvex, avascular, transparent structure composed of:

1. Lens Capsule: Basement membrane (thickest in body ~15-20 μm anteriorly)
2. Lens Epithelium: Single layer of cuboidal cells beneath anterior capsule
3. Lens Cortex: Newly formed lens fibers in periphery
4. Lens Nucleus: Compacted central lens fibers (formed in utero and childhood)

Exam Detail: Lens Transparency: Maintained by three critical features:

1. Crystallin Proteins: α-, β-, and γ-crystallins arranged in precise short-range order, creating a uniform refractive index with minimal light scatter. Crystallins comprise ~33% of lens wet weight (highest protein concentration of any tissue). [16]

2. Avascularity: Absence of blood vessels and organelles in mature lens fibers prevents light scatter.

3. Dehydration: Active transport (Na⁺/K⁺-ATPase pumps in epithelium and superficial cortex) maintains relative dehydration (~66% water vs. 75-80% in most tissues), reducing light scatter.

Molecular Mechanisms of Cataractogenesis

Exam Detail: The common final pathway of all cataracts involves protein denaturation and aggregation:

1. Oxidative Stress Hypothesis (Primary Mechanism in Age-Related Cataracts)

Step 1: Reactive Oxygen Species (ROS) Generation

• UV radiation, ionizing radiation, smoking → photochemical reactions
• Mitochondrial respiration (in epithelial cells)
• Fenton reaction (iron-catalyzed hydroxyl radical formation)

Step 2: Antioxidant Depletion

• Lens contains high concentrations of antioxidants:
  • "Glutathione (GSH): 3-10 mM (highest concentration in body)"
  • "Ascorbic acid (Vitamin C): 1-2 mM"
  • α-crystallin (heat shock protein with chaperone function)
• With aging: GSH decreases by 50-70%, ascorbate decreases by 40-60% [17]

Step 3: Protein Oxidation

• ROS → oxidation of thiol groups (-SH) in cysteine residues → disulfide bond formation (-S-S-)
• High molecular weight (HMW) protein aggregates form → light scatter → opacity
• Yellow-brown pigmentation (brunescence) from oxidized tryptophan residues

Step 4: Loss of Chaperone Function

• α-crystallin normally prevents aggregation of damaged proteins
• Oxidative damage to α-crystallin → loss of chaperone function → uncontrolled aggregation

2. Osmotic Stress Hypothesis (Diabetic and Traumatic Cataracts)

Sorbitol Pathway Activation:

Glucose → [Aldose Reductase] → Sorbitol → [Sorbitol Dehydrogenase] → Fructose

• In hyperglycemia or lens fiber disruption (trauma), glucose enters lens
• Aldose reductase converts glucose → sorbitol
• Sorbitol does not readily cross cell membranes → osmotic gradient
• Water influx → lens fiber swelling → membrane disruption → opacity
• NADPH depletion → reduced glutathione regeneration → oxidative stress [12]

3. Post-Translational Modification

• Glycation: Non-enzymatic attachment of glucose to lens proteins → AGEs
• Deamidation: Asparagine → aspartic acid (age-related)
• Truncation: Partial proteolysis of crystallins
• All disrupt protein structure → aggregation → opacity

Type-Specific Pathophysiology

---

5. Classification of Cataracts

Anatomical Classification (Most Clinically Useful)

1. Nuclear Sclerotic Cataract

Location: Central lens nucleus

Appearance:

• Yellow-brown discoloration (brunescence)
• Opalescent nuclear opacity
• Graded 1-4 or 1-5 (mild to dense)

Symptoms:

• Myopic shift ("second sight"): Nuclear sclerosis increases refractive index of nucleus → increased converging power → myopia. Elderly patients may temporarily discard reading glasses but lose distance vision.
• Gradual painless vision loss
• Yellow color tints → impaired blue-yellow color discrimination
• Better vision in dim light (pupil dilates, allows peripheral rays to bypass central opacity)

Epidemiology: Most common type; age-related

Progression: Slow (years to decades)

2. Cortical Cataract

Location: Lens cortex (peripheral)

Appearance:

• Spoke-like (radial) opacities extending from periphery toward center
• Wedge-shaped ("cuneiform") opacities
• "Waterclefts" (liquefied cortex)

Symptoms:

• Glare: Peripheral opacities scatter light, especially problematic with bright lights or car headlights
• Monocular diplopia or polyopia (multiple images)
• Variable vision depending on pupil size (worse in bright light when pupil constricts and light passes through peripheral opacities)

Epidemiology: Second most common; associated with diabetes, UV exposure

Progression: Moderate (months to years)

3. Posterior Subcapsular (PSC) Cataract

Location: Posterior cortex immediately beneath posterior capsule

Appearance:

• Granular, plaque-like opacity
• Central location (axial)

Symptoms:

• Severe glare: Central location → maximal disability in bright light (constricted pupil)
• Difficulty reading (near vision requires miosis via accommodation)
• Paradoxically better vision in dim light (pupil dilates, allowing light to bypass central opacity)
• Rapid functional decline

Epidemiology:

• Corticosteroid use (strongest association)
• Diabetes
• Young patients (less than 50 years)
• Radiation exposure
• Chronic uveitis

Progression: Rapid (months to 1-2 years)

Clinical Pearl: "The PSC-Steroid Connection": Always ask about steroid use in patients with PSC cataracts, especially young patients. Remember to inquire about:

• Inhaled steroids for asthma/COPD
• Intranasal steroids for rhinitis
• Topical ophthalmic steroids
• Systemic steroids for autoimmune/inflammatory conditions
• Potent topical dermal steroids (chronic use)

4. Anterior Subcapsular Cataract

Location: Anterior cortex beneath anterior capsule

Appearance:

• Fibrous plaque
• May have pigment (Vossius ring from iris trauma)

Causes:

• Trauma
• Chronic uveitis
• Atopic dermatitis (shield cataract)
• Phenothiazines

5. Mixed Cataracts

Most elderly patients have mixed cataracts with features of multiple types (e.g., nuclear sclerosis + cortical opacities). Classification based on predominant type.

Etiological Classification

Special Morphological Types (Exam Recognition)

Exam Detail: | Type | Appearance | Association | |------|------------|-------------| | Snowflake Cataract | White flake-like subcapsular opacities | Acute hyperglycemia in young diabetics | | Christmas Tree Cataract | Polychromatic crystalline deposits | Myotonic dystrophy (pathognomonic) | | Sunflower Cataract | Bronze/golden anterior subcapsular deposits | Wilson disease (copper deposition) | | Oil Droplet Cataract | Red reflex shows colorful oil droplet | Galactosemia | | Blue Dot Cataract | Blue/cerulean dots in cortex | Congenital; usually non-progressive; incidental | | Rosette Cataract | Flower-like pattern | Traumatic (blunt or penetrating injury) |

Grading Systems

LOCS III (Lens Opacities Classification System III): Most widely used research grading system

• Nuclear color: NC1-NC6
• Nuclear opalescence: NO1-NO6
• Cortical: C1-C5
• Posterior subcapsular: P1-P5

Clinical Utility: Standardizes cataract description for surgical planning and research; not routinely used in clinical practice.

---

6. Clinical Presentation

Symptoms

Exam Detail: The hallmark of cataracts is painless, progressive vision loss. Pain should prompt consideration of alternative or additional diagnoses (e.g., acute glaucoma, uveitis).

Clinical History: Key Questions

Clinical Pearl: Functional Assessment Over Visual Acuity: Surgical decision-making depends on functional impairment, not just Snellen acuity. Key questions:

1. "Can you see well enough to do what you want to do?"
2. "Does the vision affect your daily activities—reading, driving, watching TV?"
3. "Do you have difficulty with glare from lights at night?"
4. "Have you had any falls or near-misses because of vision?"
5. "Do you still hold a driving license? Are you meeting the visual standards?"

A patient with 6/12 vision but severe glare disability may benefit more from surgery than a patient with 6/18 vision and minimal symptoms.

Physical Examination

Visual Acuity Testing

• Distance acuity: Snellen chart (6/6, 6/9, 6/12, etc.) or LogMAR
• Near acuity: Near card (N5, N6, N8, etc.)
• Pinhole acuity: If acuity improves with pinhole → refractive error contributes; if no improvement → media opacity or retinal disease likely

Exam Detail: Pinhole Principle: Small aperture (pinhole) eliminates peripheral rays, allowing only central (paraxial) rays to reach retina. This:

1. Neutralizes refractive error (myopia, hyperopia, astigmatism)
2. Does NOT improve vision if opacity is centrally located (nuclear or PSC cataract)
3. May actually worsen vision in cortical cataracts (peripheral spokes block the pinhole rays)

Red Reflex Examination

Technique:

1. Direct ophthalmoscope set to 0 diopters (or +1 to +2 in myopic patient)
2. Stand 50 cm from patient in darkened room
3. Observe both eyes simultaneously (Bruckner test)
4. Normal: Bright, uniform orange-red reflex from both eyes

Cataract Findings:

• Reduced/diminished red reflex: Mild to moderate cataract
• Dark shadow against red reflex: Localized opacity
  • "Central dark shadow: Nuclear or PSC cataract"
  • "Peripheral spoke-like shadows: Cortical cataract"
• Absent red reflex: Dense mature/hypermature cataract

Clinical Pearl: Pediatric Red Reflex: Absent or asymmetric red reflex in an infant or child is an urgent red flag requiring same-day ophthalmology referral to exclude:

1. Retinoblastoma (leukocoria—white pupil)
2. Congenital cataract (risk of irreversible amblyopia)
3. Other causes: Persistent hyperplastic primary vitreous (PHPV), Toxocara, retinal detachment

Slit Lamp Biomicroscopy (Specialist Examination)

• Gold standard for cataract assessment
• Allows precise localization and grading of opacity type
• Assesses anterior segment for coexisting pathology (corneal disease, pseudoexfoliation, iris abnormalities)

Fundoscopy

• Purpose: Assess posterior segment for coexisting pathology that may limit post-operative visual potential
• Important findings:
  • Age-related macular degeneration (AMD)
  • Diabetic retinopathy
  • Glaucomatous optic neuropathy
  • Epiretinal membrane
• Dense cataracts may preclude fundal view → B-scan ultrasound required to exclude retinal detachment or posterior segment pathology

Additional Examination Components

---

7. Differential Diagnosis

While cataracts are usually straightforward to diagnose, other causes of gradual vision loss must be considered:

Exam Detail: "CATARACT" Mnemonic for Gradual Vision Loss:

• Cataract
• AMD (Age-Related Macular Degeneration)
• Temporal arteritis (anterior ischemic optic neuropathy)
• Alignment (binocular diplopia from muscle/nerve disease)
• Retinopathy (diabetic, hypertensive)
• Amblyopia (childhood vision loss, may present in adulthood)
• Corneal opacity (dystrophy, scar)
• Tumor (compressive optic neuropathy, intraocular tumor)

Combined Pathology

Many elderly patients have multiple causes of vision loss:

• Cataract + AMD (very common)
• Cataract + diabetic retinopathy
• Cataract + glaucoma

Clinical Implication: Pre-operative counseling must address realistic visual expectations when coexisting retinal or optic nerve disease limits post-operative visual potential.

---

8. Investigations

Essential Pre-Operative Investigations

1. Biometry (Axial Length Measurement)

Purpose: Calculate intraocular lens (IOL) power required to achieve target refraction (usually emmetropia—no glasses for distance).

Techniques:

IOL Power Calculation Formulas:

• SRK/T: Standard formula for most eyes
• Haigis: Better for short or long eyes
• Barrett Universal II: Newer generation; improved accuracy
• Hoffer Q, Holladay: Alternative formulas

Exam Detail: Biometry Errors: Refractive surprise (unexpected post-operative refraction) occurs in ~5-15% of cases, usually due to:

1. Biometry measurement error (most common)
2. Incorrect IOL power calculation formula selection
3. IOL manufacturing tolerance (±0.5 D)
4. Effective lens position (ELP) prediction error
5. Posterior capsule position changes post-operatively

Targeting emmetropia (plano) in both eyes is standard, but individualized targets may be chosen:

• Monovision: One eye targeted for distance (-0.25 to plano), other for near (-1.50 to -2.50 D)
• Mini-monovision: Smaller anisometropia (-0.75 to -1.25 D near eye)

2. Keratometry (Corneal Curvature Measurement)

• Measures corneal power (typically 42-45 D)
• Essential for IOL calculation
• Identifies corneal astigmatism (> 1.00 D may benefit from toric IOL or limbal relaxing incisions)

3. Specular Microscopy (Selective Cases)

Indications:

• Previous corneal disease
• Fuchs endothelial dystrophy
• Previous intraocular surgery
• Narrow angle-closure concerns

Purpose: Assess corneal endothelial cell density (normal > 2000 cells/mm²). Low density increases risk of post-operative corneal decompensation.

4. Optical Coherence Tomography (OCT) Macula

Indications: Not routine, but useful in:

• Suspected macular pathology (AMD, epiretinal membrane, macular hole)
• Poor fundal view due to dense cataract (if OCT can penetrate)
• Pre-operative visual potential assessment

5. B-Scan Ultrasonography

Indications: Dense cataract preventing fundal view

Purpose: Exclude:

• Retinal detachment
• Vitreous hemorrhage
• Intraocular tumor
• Posterior staphyloma (high myopia)

6. Potential Acuity Meter (PAM) or Laser Interferometry

Indications: Questionable visual potential (e.g., coexisting macular disease)

Purpose: Estimate best-corrected visual acuity achievable after cataract removal (limited utility; largely replaced by OCT)

Pre-Operative Medical Assessment

Clinical Pearl: Intraoperative Floppy Iris Syndrome (IFIS): Triad of:

1. Billowing iris
2. Progressive intraoperative pupil constriction
3. Iris prolapse through incisions

Strongest association: Tamsulosin (α₁A-blocker for BPH). Irreversible even after drug cessation. Requires surgeon awareness and modified technique (iris hooks, viscoelastic devices, reduced irrigation flow).

Always ask male patients about tamsulosin/alfuzosin use pre-operatively.

---

9. Management

Surgical Indications

Absolute Indication:

• Phacomorphic glaucoma: Mature/intumescent cataract causes pupillary block → acute angle closure → emergency surgery required

Relative Indications (Patient-Centered Decision):

• Visual impairment affecting activities of daily living (ADLs)
• Difficulty with driving, reading, work, hobbies
• Increased falls risk
• Glare disability
• Patient desire for improved vision

Exam Detail: NICE Guideline (NG77, 2017): Recommends offering cataract surgery when:

1. Visual impairment affects the person's ability to carry out daily activities, AND
2. Cataract surgery is likely to improve vision and quality of life

No specific visual acuity threshold mandates surgery. Functional impairment is paramount. A patient with 6/12 acuity but severe glare may benefit more than a patient with 6/18 acuity and minimal symptoms. [18]

Second Eye Surgery:

• NICE recommends offering second eye surgery if first eye successful and patient desires improved bilateral vision
• Benefit: Improved stereopsis, peripheral visual field, reduced aniseikonia (image size disparity)

Non-Surgical Management

Clinical Pearl: "Watchful Waiting" vs. Early Surgery: Historically, surgeons waited until cataracts were "ripe" (mature). Modern phacoemulsification allows safe surgery at any stage. Current practice: Surgery offered when symptoms warrant intervention, not based on visual acuity threshold or cataract density.

---

10. Surgical Technique: Phacoemulsification

Phacoemulsification ("phaco") is the gold standard cataract surgery technique worldwide, replacing older extracapsular cataract extraction (ECCE).

Advantages Over Extracapsular Cataract Extraction (ECCE)

Phacoemulsification Steps (Detailed)

Exam Detail: #### 1. Anesthesia

Options:

• Topical (Most common): Proxymetacaine or tetracaine drops ± intracameral lidocaine

  • "Advantages: No needle, immediate visual recovery, no globe akinesia risk"
  • "Disadvantages: Patient must cooperate; no akinesia (eye may move)"

• Sub-Tenon's (Peribulbar): Blunt cannula delivers anesthetic into sub-Tenon's space

  • "Advantages: Akinesia (eye immobile), analgesia, suitable for anxious patients"
  • "Disadvantages: Needle required, subconjunctival hemorrhage risk, delayed visual recovery"

• General Anesthesia: Reserved for children, adults unable to cooperate, severe anxiety

2. Clear Corneal Incision (2.2-3.0 mm)

• Location: Typically temporal (avoids superior cornea, less astigmatism) or superior
• Tri-planar incision: Self-sealing (no sutures required)
• Secondary incisions: 1-2 side-port incisions (1.0-1.5 mm) for instrument access

3. Viscoelastic Injection

• Cohesive viscoelastic (sodium hyaluronate) injected into anterior chamber
• Functions: Maintain space, protect corneal endothelium, stabilize anterior chamber

4. Continuous Curvilinear Capsulorhexis (CCC)

• Critical step: Circular tear in anterior lens capsule (5.0-5.5 mm diameter)
• Creates opening for lens removal and IOL placement
• Must be continuous (no radial tears) to prevent capsule rupture during phaco

Clinical Pearl: Capsulorhexis Challenges:

• White/mature cataract: Anterior capsule may be under tension → "Argentinian flag sign" (capsule tear extending radially). Use capsule staining (trypan blue) to visualize.
• Posterior polar cataract: Thin posterior capsule adherent to opacity → high rupture risk.

5. Hydrodissection

• Balanced salt solution (BSS) injected beneath anterior capsule to separate cortex from capsule
• Creates fluid wave → separates lens nucleus from cortex and capsule → allows rotation and manipulation

6. Phacoemulsification (Nucleus Removal)

Technique Options:

Phacoemulsification Probe:

• Ultrasound tip vibrating at 20-60 kHz
• Emulsifies lens tissue → aspirated through probe
• Irrigation maintains anterior chamber stability

Power Modulation: Surgeons use intermittent ultrasound (pulse, burst modes) to reduce heat generation and endothelial damage.

7. Cortical Aspiration (Irrigation/Aspiration, I/A)

• Bimanual I/A probe removes residual cortical material
• Critical: Complete cortex removal prevents inflammation and reduces PCO risk

8. Intraocular Lens (IOL) Insertion

• Foldable IOL (acrylic or silicone) inserted through 2.2-3.0 mm incision using injector
• IOL unfolds in capsular bag
• Haptics (IOL arms) center the lens in bag
• Viscoelastic removed by irrigation/aspiration (prevents IOP spike)

9. Wound Hydration and Closure

• Incisions hydrated with BSS → stromal edema seals wound (self-sealing)
• Wound tested for leak (Seidel test with fluorescein)
• Sutures rarely needed (only if wound leak)

10. Intracameral Antibiotic (Selective)

• Cefuroxime 1 mg or moxifloxacin injected into anterior chamber at end of surgery
• Evidence: ESCRS study showed 5× reduction in endophthalmitis with intracameral cefuroxime (0.029% vs. 0.175%). [19]
• Increasingly routine in UK/Europe; less common in US

Intraocular Lens (IOL) Options

Exam Detail: #### Monofocal IOL (Standard)

Function: Single focal point (usually distance)

Advantages:

• Excellent distance vision
• Lowest cost (NHS-funded)
• Best contrast sensitivity
• No haloes or glare

Disadvantages:

• Requires reading glasses for near vision
• Bifocals or progressive lenses needed for intermediate/near

Toric IOL

Function: Corrects corneal astigmatism (> 1.00 D)

Advantages:

• Reduces spectacle dependence for distance vision
• Sharper distance vision without glasses

Disadvantages:

• Requires precise alignment (rotation post-op reduces efficacy)
• More expensive
• Still requires reading glasses

Multifocal IOL

Function: Multiple focal points (distance + intermediate + near)

Advantages:

• Spectacle independence for most tasks
• Can read and drive without glasses

Disadvantages:

• Haloes and glare around lights (dysphotopsia)—problematic for night driving
• Reduced contrast sensitivity
• Not suitable for patients with macular disease, glaucoma, or high visual demands (e.g., professional drivers)
• Expensive (private, not routinely NHS-funded)
• Neuroadaptation period (3-6 months)

Extended Depth of Focus (EDOF) IOL

Function: Elongated single focal point providing distance + intermediate vision

Advantages:

• Better intermediate vision than monofocal (computer, dashboard)
• Fewer dysphotopsias than multifocal
• Good contrast sensitivity

Disadvantages:

• May still require reading glasses for small print
• More expensive

Monovision (Pseudophakic Monovision)

Technique: Dominant eye targeted for distance (plano), non-dominant eye targeted for near (-1.50 to -2.00 D myopia)

Advantages:

• Reduced spectacle dependence using monofocal IOLs
• No premium lens cost
• Less dysphotopsia than multifocal

Disadvantages:

• Reduced stereopsis (depth perception)
• May affect driving safety (some patients cannot tolerate)
• Trial with contact lenses pre-operatively recommended

---

11. Post-Operative Care

Immediate Post-Operative Period (Day 1)

Day 1 Review (Routine or as needed):

• Visual acuity check (may be reduced due to corneal edema, pupil dilation)
• IOP measurement (risk of IOP spike from retained viscoelastic)
• Slit lamp examination: Check wound integrity, anterior chamber depth, IOL position, corneal clarity

Normal Findings Day 1:

• Mild corneal edema (clears within 1-7 days)
• Mildly reduced vision (6/9 to 6/18 typical)
• Trace anterior chamber cells (inflammation)

Abnormal Findings Requiring Action:

• Severe pain (consider endophthalmitis, elevated IOP, corneal abrasion)
• Vision worse than 6/60 (exclude complications)
• IOP > 30 mmHg (retained viscoelastic, steroid response, pupillary block)
• Hypopyon (pus level—endophthalmitis until proven otherwise)
• Wound leak (Seidel test positive)

Post-Operative Medications

Tapering Schedule (Example):

• Weeks 1-2: QID (4× daily)
• Weeks 3-4: TDS (3× daily)
• Week 4: BD (2× daily)
• Week 5: OD (1× daily)
• Stop

Clinical Pearl: NSAID Use: Routine use of topical NSAIDs post-operatively is debated but increasingly common. Benefits:

• Reduced cystoid macular edema (CMO) risk, especially in diabetics
• Improved patient comfort
• Potential faster visual recovery

Risk: Corneal melts (rare) in susceptible patients (rheumatoid arthritis, Sjogren's syndrome, previous corneal surgery). [20]

Post-Operative Instructions

DO:

• Use eye drops as prescribed
• Wear eye shield at night for 1 week (prevent inadvertent rubbing)
• Attend follow-up appointments
• Report any pain, redness, vision loss immediately

DO NOT (typically for 1-2 weeks):

• Rub the eye
• Swim (risk of infection)
• Heavy lifting or strenuous exercise (risk of IOP spike)
• Wear eye makeup (risk of infection)
• Get water/soap in the eye during showering (protect eye)

Follow-Up Schedule

Standard:

• Week 1-2: Post-operative check (many surgeons discharge at this point if uneventful)
• Week 4-6: Refraction and final prescription (allow refractive stability)

Optometrist Follow-Up: Most uncomplicated cases discharged to optometrist for final refraction and spectacle prescription at 4-6 weeks.

Ophthalmology Follow-Up: Reserved for complicated cases, coexisting ocular disease (glaucoma, AMD, diabetic retinopathy).

Expected Visual Recovery Timeline

Factors Delaying Recovery:

• Corneal endothelial dysfunction (Fuchs dystrophy)
• Macular disease (AMD, diabetic maculopathy)
• Severe inflammation
• Complications (CMO, retained lens fragments)

---

12. Complications

Intraoperative Complications

Exam Detail: #### Posterior Capsule Rupture (PCR)

Incidence: 1-2% (higher in training cases, dense cataracts, posterior polar cataracts)

Causes:

• Excessive phacoemulsification power
• Posterior polar cataract (thin capsule)
• Radial capsulotomy tear extending posteriorly
• Zonular weakness (pseudoexfoliation, high myopia, trauma)

Consequences:

• Vitreous prolapse into anterior chamber
• Nucleus/cortex fragment drop into vitreous cavity
• IOL may require anterior chamber or sulcus placement (not in-the-bag)
• Increased risk of:
  • Retinal detachment (1-2% vs. 0.3-0.7% without PCR)
  • Cystoid macular edema
  • Endophthalmitis

Management:

1. Recognize early (sudden deepening of anterior chamber, vitreous in wound)
2. Stop phaco immediately
3. Anterior vitrectomy (remove prolapsed vitreous)
4. Retrieve lens fragments from anterior chamber/vitreous if accessible
5. IOL placement: In-the-bag if possible; otherwise sulcus or AC-IOL
6. Vitreoretinal referral if large nucleus fragment dropped (vitrectomy + lensectomy)

Early Post-Operative Complications (less than 6 Weeks)

Exam Detail: #### Endophthalmitis (Acute Post-Operative)

Definition: Infection inside the eye (bacterial or fungal)

Incidence: 0.03-0.2% (varies by region, surgical technique, use of intracameral antibiotics) [19]

Timing:

• Acute: 1-7 days post-op (most common: 2-4 days)
• Chronic (Propionibacterium acnes): Weeks to months

Causative Organisms:

• Coagulase-negative Staphylococci (70%): S. epidermidis (most common)
• Staphylococcus aureus (10-15%): More virulent
• Streptococcus species (10%): Aggressive
• Gram-negative bacilli (5%): Pseudomonas (devastating)
• Fungi (less than 5%): Candida, Aspergillus (chronic, weeks post-op)

Symptoms:

• Severe pain (red flag—cataracts are painless; post-op endophthalmitis is painful)
• Decreased vision (often to counting fingers or worse)
• Photophobia
• Red eye

Signs:

• Hypopyon (layered pus in anterior chamber)—hallmark finding
• Severe anterior chamber inflammation (> 3+ cells, flare)
• Vitreous haze/opacity
• Reduced or absent red reflex
• Lid edema, chemosis

Diagnosis:

• Clinical (do not delay treatment for laboratory confirmation)
• Vitreous and aqueous tap: Send for Gram stain, culture, sensitivities

Management (URGENT—same-day ophthalmology referral):

1. Intravitreal Antibiotics (mainstay):

   • Vancomycin 1 mg/0.1 mL (Gram-positive coverage)
   • Ceftazidime 2.25 mg/0.1 mL OR amikacin 0.4 mg/0.1 mL (Gram-negative coverage)
   • Injected directly into vitreous cavity

2. Vitreous Tap ± Vitrectomy:

   • Tap and inject: Mild cases (vision > 6/60)
   • Vitrectomy: Severe cases (vision less than 6/60), better outcomes in EVS trial [21]

3. Topical Fortified Antibiotics (adjunct):

   • Vancomycin 50 mg/mL hourly
   • Ceftazidime 50 mg/mL hourly

4. Topical Corticosteroids: Prednisolone 1% hourly (after antibiotics started)

5. Systemic Antibiotics: Controversial; not recommended in EVS trial

Prognosis:

• Early detection and treatment: 60-80% achieve ≥6/12 vision
• Delayed treatment or virulent organism (S. aureus, Streptococcus, Gram-negatives): 30-50% achieve ≥6/12; 10-20% lose vision completely or require evisceration

Clinical Pearl: Endophthalmitis Clinical Trap: Pain + vision loss post-cataract surgery = endophthalmitis until proven otherwise. DO NOT assume "normal post-op inflammation." Same-day ophthalmology referral required.

Differential includes:

• Severe anterior uveitis (non-infectious)
• Retained lens fragment
• Toxic anterior segment syndrome (TASS)—sterile inflammation, occurs Day 1-2 (earlier than infective endophthalmitis), less severe

Late Post-Operative Complications (> 6 Weeks)

Exam Detail: #### Posterior Capsular Opacification (PCO)

Definition: Opacification of the posterior capsule behind the IOL due to lens epithelial cell proliferation and migration.

Synonyms: "After-cataract," "Secondary cataract" (misnomer—not a new cataract)

Incidence:

• 1 year: 5-10%
• 5 years: 20-40%
• Reduced with modern square-edge IOL designs (barrier effect prevents cell migration)

Pathophysiology:

1. Residual lens epithelial cells (LECs) remain after cataract surgery
2. LECs undergo epithelial-mesenchymal transition (EMT) → myofibroblasts
3. Cells migrate posteriorly along capsule behind IOL
4. Proliferation and matrix production → capsule opacification

Types:

• Fibrotic PCO: Fibrous metaplasia, contraction, capsular wrinkling
• Pearl PCO: Elschnig pearls (bladder cells)—residual LECs undergo aberrant differentiation

Symptoms:

• Gradual blurred vision (months to years post-cataract surgery)
• Glare (recurrence of pre-operative symptoms)
• Patients often believe "cataract has grown back"

Diagnosis:

• Slit lamp: Visible opacity on posterior capsule behind IOL
• Reduced red reflex (dark shadow posterior to IOL)

Treatment: YAG Laser Posterior Capsulotomy

Procedure:

1. Dilate pupil
2. Topical anesthetic
3. Nd:YAG laser (1064 nm) focused on posterior capsule
4. Create central opening (3-4 mm) in capsule
5. Immediate visual improvement in most cases
6. Duration: 5-10 minutes; office procedure

Efficacy: > 95% achieve visual improvement

Complications of YAG Capsulotomy:

• IOP spike (20-30%): Transient elevation in first 1-2 hours; treat with topical IOP-lowering drops
• Retinal detachment (0.5-2%): Risk higher in young myopes
• IOL pitting/damage (rare): Laser accidentally hits IOL
• Cystoid macular edema (1-2%): Particularly if YAG done early (less than 3 months post-op)
• Anterior uveitis (5-10%): Mild inflammation; treat with topical steroids

Timing: Generally delayed until ≥3 months post-cataract surgery to reduce CMO risk.

Exam Detail: #### Cystoid Macular Edema (CMO, Irvine-Gass Syndrome)

Pathophysiology:

• Surgical trauma → prostaglandin release → breakdown of blood-retinal barrier
• Fluid accumulates in outer plexiform and inner nuclear layers of macula → cystoid spaces
• Peaks at 4-6 weeks post-op

Risk Factors:

• Diabetes
• Uveitis
• Epiretinal membrane
• Retinal vein occlusion
• Complicated surgery (PCR, vitreous loss)
• Prolonged surgery time

Diagnosis:

• Clinical: Reduced vision, OCT shows cystoid spaces in macula
• OCT: Gold standard—shows cystoid spaces, increased macular thickness

Treatment:

1. Topical NSAIDs (ketorolac, nepafenac) QID for 4-8 weeks
2. Topical Corticosteroids (prednisolone 1%) QID for 4-8 weeks
3. Sub-Tenon's Triamcinolone injection (if refractory)
4. Oral Acetazolamide (250 mg BD) in refractory cases
5. Intravitreal Corticosteroid (dexamethasone implant, triamcinolone) in severe refractory cases

Prognosis: 80-90% resolve within 6 months with treatment. Chronic CMO (> 6 months) has poorer visual prognosis.

---

13. Prognosis and Outcomes

Visual Outcomes

Exam Detail: Expected Outcomes (UK Royal College of Ophthalmologists National Ophthalmology Database Audit): [3]

• 95-98% achieve driving vision standard (6/12 or better) post-operatively
• 85-90% achieve 6/6 or better
• Spectacle independence for distance: 60-70% (with monofocal IOL targeted for emmetropia)
• Spectacle independence for near: less than 10% (with monofocal IOL)

Factors Limiting Visual Outcome:

1. Pre-existing macular disease (AMD, diabetic maculopathy, epiretinal membrane)—most common
2. Glaucoma (advanced optic neuropathy)
3. Amblyopia (childhood vision loss)
4. Corneal disease (Fuchs dystrophy, scarring)
5. Surgical complications (CMO, retinal detachment, endophthalmitis)

Quality of Life Improvement

Cataract surgery produces one of the largest quality-of-life improvements of any medical intervention:

Safety Profile

Cataract surgery is one of the safest surgical procedures:

---

14. Prevention and Risk Reduction

Primary Prevention (Delaying Cataract Onset)

Exam Detail: Evidence-Based Strategies:

Nutritional Interventions:

The Age-Related Eye Disease Study (AREDS, AREDS2) found:

• High-dose antioxidant supplements (vitamins C, E, beta-carotene, zinc) did NOT reduce cataract risk in the general population [22]
• Antioxidant-rich diet (fruits, vegetables, fish) shows modest benefit in observational studies but lacks RCT support

Current Recommendation: Balanced diet rich in fruits and vegetables; no specific supplementation recommended for cataract prevention.

Secondary Prevention (Screening and Early Detection)

---

15. Special Populations

Diabetes

Considerations:

• Earlier onset: Cataracts develop 10-20 years earlier than non-diabetics
• Rapid progression: Particularly PSC cataracts
• Coexisting retinopathy: Pre-operative retinal assessment essential
• Post-operative CMO risk: Higher risk (4-10% vs. 1-2% in non-diabetics)
• Refractive surprise: Fluctuating blood glucose → fluctuating refractive error → delay final refraction until glucose stabilized

Management:

• Optimize HbA1c pre-operatively (target less than 8.5% if possible)
• Treat significant diabetic retinopathy before or concurrent with cataract surgery
• Consider intravitreal anti-VEGF if DMO present
• Routine topical NSAIDs post-operatively to reduce CMO risk

Steroid Users

Considerations:

• PSC cataracts: Dose-dependent and cumulative risk
• All routes: Systemic, inhaled, intranasal, topical ophthalmic, dermal
• Monitoring: Regular eye examinations if on chronic high-dose steroids

Prevention:

• Use lowest effective steroid dose
• Consider steroid-sparing agents (DMARDs, biologics)
• Early cataract surgery if vision affected

Myotonic Dystrophy

Considerations:

• Christmas tree cataracts: Polychromatic crystals; pathognomonic
• Multisystem disease: Cardiac conduction defects, respiratory muscle weakness
• Anesthetic risk: Aspiration risk, cardiac arrhythmias, malignant hyperthermia susceptibility
• Surgical risk: Higher complication rates (zonular weakness)

Management:

• Pre-operative cardiology assessment (ECG, ± Holter monitor)
• Anesthetic assessment (may require general anesthesia with precautions)
• Intraoperative: Consider capsular tension ring (CTR) for zonular support

Congenital Cataracts

Etiology:

Management:

• Urgent referral if unilateral or bilateral dense cataract (prevent amblyopia)
• Critical period: First 6-8 weeks of life (bilateral dense cataracts require urgent surgery)
• Unilateral cataracts: Surgery ideally within first 6 weeks
• Post-operative: Aggressive amblyopia treatment (patching, atropine penalization)

---

16. Examination Focus (Viva and OSCE Scenarios)

Viva Question 1: Management of Post-Operative Endophthalmitis

Examiner: "A 72-year-old woman presents 3 days after routine cataract surgery with severe pain and reduced vision. On examination, she has a hypopyon. What is your diagnosis and management?"

Exam Detail: Model Answer:

"This presentation is highly concerning for acute post-operative endophthalmitis, which is a surgical emergency.

Immediate Management:

1. Urgent same-day ophthalmology referral—this is sight-threatening
2. Do not delay referral for investigations or treatment

Ophthalmology Management (for context):

1. Vitreous and aqueous tap for microbiological culture and sensitivities
2. Intravitreal antibiotics (mainstay):
   • Vancomycin 1 mg (Gram-positive coverage)
   • Ceftazidime 2.25 mg or amikacin 0.4 mg (Gram-negative coverage)
3. Vitrectomy if vision worse than 6/60 (Endophthalmitis Vitrectomy Study showed improved outcomes)
4. Topical fortified antibiotics (adjunct)
5. Topical corticosteroids (after antibiotics started)

Causative Organisms: Most commonly coagulase-negative Staphylococci (S. epidermidis ~70%), but can be S. aureus, Streptococcus, or Gram-negatives (worse prognosis).

Prognosis: Early detection and treatment can salvage vision in 60-80% of cases, but delayed treatment or virulent organisms may result in permanent severe vision loss or loss of the eye."

Viva Question 2: IOL Calculation and Biometry

Examiner: "How do you calculate the appropriate intraocular lens power for a cataract surgery patient?"

Exam Detail: Model Answer:

"IOL power calculation requires biometry to measure three key parameters:

1. Axial Length (AL): The distance from corneal surface to retinal pigment epithelium

• Measured by optical biometry (IOLMaster, Lenstar)—gold standard
• Or A-scan ultrasound if optical biometry fails

2. Keratometry (K): Corneal curvature/power

• Measured by keratometer or corneal topography
• Average corneal power is ~43-44 diopters

3. Anterior Chamber Depth (ACD): Distance from cornea to lens

• Used to predict effective lens position (ELP) after IOL insertion

IOL Power Calculation Formulas:

• SRK/T: Standard formula for most eyes
• Haigis, Barrett Universal II: Better for extreme axial lengths (short or long eyes)

Target Refraction:

• Emmetropia (plano): Most common target—good distance vision, requires reading glasses
• Monovision: Dominant eye for distance, non-dominant eye for near (-1.50 to -2.00 D)
• Mild myopia: Some elderly patients prefer slight myopia (-0.50 to -1.00 D) for reading

Accuracy: Modern biometry achieves ±0.50 D in 90-95% of cases, but refractive surprises occur in 5-10% due to measurement error, formula limitations, or post-operative lens position variation."

Viva Question 3: Posterior Capsular Opacification (PCO)

Examiner: "A patient who had cataract surgery 2 years ago presents with gradual blurred vision. What is the likely diagnosis and management?"

Exam Detail: Model Answer:

"The most likely diagnosis is posterior capsular opacification (PCO), also called 'after-cataract' or secondary cataract, though this is a misnomer as it is not a new cataract.

Pathophysiology: Residual lens epithelial cells proliferate and migrate along the posterior capsule behind the IOL, causing opacification. This occurs in 20-40% of patients within 5 years of surgery.

Diagnosis:

• Clinical history: Gradual blurred vision months to years post-cataract surgery
• Examination: Slit lamp shows opacity on posterior capsule behind IOL; reduced red reflex

Treatment: YAG Laser Posterior Capsulotomy:

• Office-based procedure (5-10 minutes)
• Nd:YAG laser creates a central opening in the posterior capsule
• Immediate visual improvement in > 95% of cases

Complications of YAG Capsulotomy:

1. IOP spike (20-30%)—transient, treat with topical IOP-lowering drops
2. Retinal detachment (0.5-2%)—higher risk in young myopes
3. Cystoid macular edema (1-2%)—especially if YAG done early
4. IOL pitting (rare)

Timing: Generally wait ≥3 months post-cataract surgery to minimize CMO risk.

Prognosis: Excellent—most patients achieve immediate visual improvement, and PCO does not recur after YAG capsulotomy."

OSCE Station: Explaining Cataract Surgery to a Patient

Scenario: You are a junior doctor in ophthalmology clinic. A 70-year-old patient has been diagnosed with cataracts and is listed for surgery. Explain the procedure and answer their questions.

Exam Detail: Model Explanation:

"What is a cataract? A cataract is when the natural lens inside your eye becomes cloudy, like a frosted window. This makes your vision blurry and can cause glare from lights. It's very common as we get older—most people over 70 have some cataract.

What does the operation involve? The operation is called phacoemulsification. We make a tiny 2-3 mm cut in your eye—so small it usually doesn't need stitches. We use sound waves to break up the cloudy lens and remove it, then insert a new clear plastic lens that stays in your eye permanently. You won't feel it.

Anesthesia: We use numbing eye drops, so you'll be awake but won't feel pain. You may see lights and colors during the operation, but no sharp images. It takes about 15-30 minutes.

Recovery: Your vision improves quickly—usually within a few days. You'll use eye drops for about 4 weeks to prevent infection and reduce inflammation. We recommend avoiding swimming and heavy lifting for 1-2 weeks. You can return to most normal activities within a few days.

Will I need glasses? Most patients still need reading glasses after surgery, as the standard lens gives you good distance vision but not near vision. Some people choose premium lenses for better near vision, but these are not usually funded by the NHS.

Risks: Cataract surgery is very safe. Over 95% of people achieve good vision. Serious complications like infection (endophthalmitis) are very rare—less than 1 in 1,000. We take many precautions to keep the operation as safe as possible.

Long-term: Some people develop clouding of the membrane behind the lens (PCO or 'after-cataract') months or years later. This is easily treated with a quick laser procedure in the clinic.

Do you have any questions?"

Common Questions:

• "Will I feel it?" → No, eye will be numb; no pain during surgery
• "Can both eyes be done together?" → Usually one at a time, a few weeks apart
• "What if it goes wrong?" → Very rare; we discuss all risks in detail beforehand

---

17. Patient/Layperson Explanation

What is a Cataract?

"Inside your eye, there's a clear lens, similar to the lens in a camera. As you get older, this lens can become cloudy—we call this a cataract. It's like looking through a foggy or frosted window. Cataracts are very common; most people over 70 have some degree of cataract. The good news is that cataracts can be removed with surgery and your vision restored."

What Causes Cataracts?

"Most cataracts are simply due to aging—the proteins in the lens break down over many years. Other causes include:

• Smoking (doubles your risk)
• Diabetes (causes earlier cataracts)
• Steroid medications (tablets, inhalers, eye drops)
• Injury to the eye
• Too much sunlight (UV rays)

Some babies are born with cataracts, but these are rare and usually related to infections during pregnancy or genetic conditions."

What Are the Symptoms?

"Cataracts cause:

• Blurry vision, as if you're looking through a dirty window
• Glare from car headlights or bright lights
• Faded colors—everything looks washed out or yellowish
• Difficulty reading, especially in dim light
• Frequent changes in your glasses prescription

Cataracts are painless. If you have eye pain, it's likely something else, and you should see a doctor urgently."

How Are Cataracts Treated?

"The only treatment that works is surgery to remove the cloudy lens and replace it with a clear artificial lens. Surgery is not urgent—we operate when the cataract affects your daily life (driving, reading, watching TV).

The Operation:

• Done as day surgery—you go home the same day
• Takes 15-30 minutes
• Numbing eye drops (you're awake but don't feel pain)
• Tiny 2-3 mm cut in the eye
• Old cloudy lens removed using sound waves and suction
• New clear plastic lens inserted—it stays in your eye permanently

Recovery:

• Vision improves within days
• Eye drops for 4 weeks
• Avoid rubbing your eye, swimming, and heavy lifting for 1-2 weeks

Results:

• Over 95% of people see much better after surgery
• You'll likely still need reading glasses
• Very safe—serious problems are rare (less than 1 in 1,000)"

What If I Don't Have Surgery?

"Cataracts don't harm your eye permanently—they just make your vision worse. If you can see well enough for your daily activities, you don't need surgery. However, as cataracts progress, you may:

• Fail the driving vision test
• Have difficulty reading or watching TV
• Have more falls due to poor vision

When cataracts affect your quality of life, that's the right time for surgery."

---

18. Key Guidelines and Evidence

Major Guidelines

Landmark Studies

Exam Detail: | Study | Year | Key Findings | Impact | |-------|------|--------------|--------| | Endophthalmitis Vitrectomy Study (EVS) [21] | 1995 | Vitrectomy improves outcomes in endophthalmitis with vision less than 6/60; intravitreal antibiotics essential; systemic antibiotics no added benefit | Standard of care for endophthalmitis management | | ESCRS Endophthalmitis Study [19] | 2007 | Intracameral cefuroxime 1 mg reduces endophthalmitis rate 5× (0.029% vs. 0.175%); topical levofloxacin no added benefit | Widespread adoption of intracameral antibiotics in Europe/UK | | AREDS/AREDS2 [22] | 2001/2013 | High-dose antioxidant supplements do NOT reduce cataract incidence or progression in general population | No routine supplementation recommended for cataract prevention | | Blue Mountains Eye Study [5] | 1992-ongoing | Established prevalence, risk factors, and progression rates of age-related cataracts in Australian population | Epidemiological foundation for cataract research | | UK National Ophthalmology Database (NOD) Audit [3] | Annual | Tracks outcomes of cataract surgery across UK; 95-98% achieve ≥6/12 vision; PCR rate 1.9%; endophthalmitis rate 0.04% | Quality benchmarking and audit standards |

---

19. Summary: High-Yield Exam Facts

Clinical Pearl: Cataract Exam Essentials:

1. Leading cause of reversible blindness worldwide (51% of global blindness)

2. Nuclear sclerotic cataract:

   • Most common type; age-related
   • Yellow-brown; myopic shift ("second sight")
   • Slow progression

3. Cortical cataract:

   • Spoke-like opacities
   • Severe glare (especially from car headlights)
   • Associated with diabetes, UV exposure

4. Posterior subcapsular (PSC) cataract:

   • Steroids (all routes—systemic, inhaled, topical)
   • Rapid progression; severe glare; difficulty reading
   • Better vision in dim light (pupil dilates to bypass central opacity)

5. Phacoemulsification: Gold standard surgery

   • 2-3 mm incision; ultrasound breaks up lens; IOL inserted
   • Day case; topical anesthesia; 95-98% achieve driving vision

6. Endophthalmitis: Nightmare complication

   • 0.03-0.2% incidence
   • Pain + vision loss + hypopyon (pus level)
   • Emergency: Intravitreal antibiotics (vancomycin + ceftazidime/amikacin)

7. Posterior capsular opacification (PCO):

   • 20-40% at 5 years
   • "After-cataract"—blurred vision months/years post-op
   • Treat with YAG laser capsulotomy (95% success; 5-10 min procedure)

8. Red Reflex:

   • Reduced/absent in cataract
   • Absent in infant = urgent referral (retinoblastoma or congenital cataract → amblyopia risk)

9. IOL Calculation: Biometry (axial length + keratometry) → IOL power formula (SRK/T, Haigis)

10. Diabetes: 2-5× risk; earlier onset; "snowflake cataract" in young diabetics (sorbitol pathway); higher CMO risk post-op

11. Myotonic dystrophy: "Christmas tree cataract" (polychromatic crystals)—pathognomonic

12. Surgical Complications:

    • Intraoperative: Posterior capsule rupture (PCR) 1-2%
    • Early post-op: Endophthalmitis, elevated IOP, corneal edema
    • Late post-op: PCO, CMO, retinal detachment

13. Quality Metrics:

    • PCR rate less than 2%
    • Endophthalmitis rate less than 0.1%
    • ≥6/12 vision in 95-98%

---

20. References

1. Bourne RR, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health. 2013;1(6):e339-e349. doi:10.1016/S2214-109X(13)70113-X. PMID: 25104599

2. Khairallah M, Kahloun R, Bourne R, et al. Number of People Blind or Visually Impaired by Cataract Worldwide and in World Regions, 1990 to 2010. Invest Ophthalmol Vis Sci. 2015;56(11):6762-6769. doi:10.1167/iovs.15-17201. PMID: 26567788

3. Day AC, Donachie PH, Sparrow JM, Johnston RL; Royal College of Ophthalmologists' National Ophthalmology Database. The Royal College of Ophthalmologists' National Ophthalmology Database study of cataract surgery: report 1, visual outcomes and complications. Eye (Lond). 2015;29(4):552-560. doi:10.1038/eye.2015.3. PMID: 25679413

4. Klein BE, Klein R, Linton KL. Prevalence of age-related lens opacities in a population. The Beaver Dam Eye Study. Ophthalmology. 1992;99(4):546-552. doi:10.1016/s0161-6420(92)31934-7. PMID: 1584573

5. Mitchell P, Cumming RG, Attebo K, Panchapakesan J. Prevalence of cataract in Australia: the Blue Mountains eye study. Ophthalmology. 1997;104(4):581-588. doi:10.1016/s0161-6420(97)30266-8. PMID: 9111249

6. Zetterberg M. Age-related eye disease and gender. Maturitas. 2016;83:19-26. doi:10.1016/j.maturitas.2015.10.005. PMID: 26520247

7. West SK, Valmadrid CT. Epidemiology of risk factors for age-related cataract. Surv Ophthalmol. 1995;39(4):323-334. doi:10.1016/s0039-6257(05)80110-9. PMID: 7725232

8. Christen WG, Glynn RJ, Ajani UA, et al. Smoking cessation and risk of age-related cataract in men. JAMA. 2000;284(6):713-716. doi:10.1001/jama.284.6.713. PMID: 10927779

9. Kelly SP, Thornton J, Edwards R, Sahu A, Harrison R. Smoking and cataract: review of causal association. J Cataract Refract Surg. 2005;31(12):2395-2404. doi:10.1016/j.jcrs.2005.06.039. PMID: 16473237

10. McCarty CA, Taylor HR. A review of the epidemiologic evidence linking ultraviolet radiation and cataracts. Dev Ophthalmol. 2002;35:21-31. doi:10.1159/000060807. PMID: 12061276

11. Hiratsuka Y, Li G. Alcohol and eye diseases: a review of epidemiologic studies. J Stud Alcohol Drugs. 2001;62(3):397-402. PMID: 11414351

12. Pollreisz A, Schmidt-Erfurth U. Diabetic cataract-pathogenesis, epidemiology and treatment. J Ophthalmol. 2010;2010:608751. doi:10.1155/2010/608751. PMID: 20634936

13. James ER. The etiology of steroid cataract. J Ocul Pharmacol Ther. 2007;23(5):403-420. doi:10.1089/jop.2006.0067. PMID: 17900232

14. Jick SS, Vasilakis-Scaramozza C, Maier WC. The risk of cataract among users of inhaled steroids. Epidemiology. 2001;12(2):229-234. doi:10.1097/00001648-200103000-00015. PMID: 11246585

15. Leuschen J, Mortensen EM, Frei CR, Mansi EA, Panday V, Mansi I. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol. 2013;131(11):1427-1434. doi:10.1001/jamaophthalmol.2013.4575. PMID: 23970168

16. Basak A, Bateman O, Slingsby C, et al. High-resolution X-ray crystal structures of human gammaD crystallin (1.25 A) and the R58H mutant (1.15 A) associated with aculeiform cataract. J Mol Biol. 2003;328(5):1137-1147. doi:10.1016/s0022-2836(03)00375-9. PMID: 12729747

17. Spector A. Oxidative stress-induced cataract: mechanism of action. FASEB J. 1995;9(12):1173-1182. doi:10.1096/fasebj.9.12.7672510. PMID: 7672510

18. National Institute for Health and Care Excellence (NICE). Cataracts in adults: management. NICE guideline [NG77]. Published October 2017. https://www.nice.org.uk/guidance/ng77

19. ESCRS Endophthalmitis Study Group. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007;33(6):978-988. doi:10.1016/j.jcrs.2007.02.032. PMID: 17531690

20. Ahmadi Hosseini SM, Khalilpour S, Mozafari M, Khosravi Z, Djalilian AR. Corneal melting after cataract surgery with topical NSAID use: A systematic review and meta-analysis. Int Ophthalmol. 2021;41(4):1517-1530. doi:10.1007/s10792-020-01672-w. PMID: 33404966

21. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995;113(12):1479-1496. doi:10.1001/archopht.1995.01100120009001. PMID: 7487614

22. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19):2005-2015. doi:10.1001/jama.2013.4997. PMID: 23644932

---

Medical Disclaimer: This content is for educational purposes and clinical reference only. All treatment decisions should be made in consultation with qualified healthcare professionals and based on individual patient circumstances. If you experience vision problems, seek evaluation by an ophthalmologist or optometrist.